Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT05419492 is registered in ClinicalTrials.gov with Encoded Therapeutics as lead sponsor.

NCT NCT05419492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05419492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome
Lead sponsor
Encoded Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 14, 2024
Completion date
January 31, 2033
Enrollment
47 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome